Clinical Trial

The Application of Positive End-Expiratory Pressure in Out-of-Hospital Cardiac Arrest: The Lazarus-PEEP Trial.

Study acronym: Lazarus-PEEP
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 21, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn whether using Positive End-Expiratory Pressure (PEEP) during cardiopulmonary resuscitation (CPR) improves outcomes for adults who experience out-of-hospital cardiac arrest, a condition where the heart suddenly stops beating. PEEP is used during ventilation, which may enhance oxygen levels by keeping the airways open throughout CPR. This study aims to determine if using PEEP during CPR helps restart the heart more effectively, improves survival rates, and enhances survival with good neurologic outcomes after a cardiac arrest compared to standard CPR without PEEP. Researchers will randomly assign participants to one of two groups: one receiving CPR with PEEP set at 5 cm of water pressure and the other receiving standard CPR without PEEP. Participants will be treated by emergency medical teams trained in advanced life support, and specialised sensors will measure airflow and airway pressure during resuscitation. Additionally, the study will evaluate potential side effects associated with PEEP, such as increased pressure within the chest or lung injuries. Findings from this trial will guide recommendations on the usage of PEEP in standard CPR practices to potentially improve patient outcomes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-14; most recent amendment 2026-01-20.
Status change: Not Yet Recruiting → Recruiting 2025-05-12
Trial Details
NCT Number NCT06939335
Lead Sponsor University Hospital, Ghent
Conditions Cardiac Arrest (CA), Out-of-hospital Cardiac Arrest (OHCA), Positive End-expiratory Pressure (PEEP), Ventilation During Resuscitation
Enrollment 132 participants
Start Date 2025-04-25
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-21